A great deal of writing about ibogaine moves straight from a list of receptors to an explanation of how it works. The list is real. The explanation does not follow from it, and the researchers who assembled the list say so explicitly. This entry goes through the receptor evidence family by family, states what each piece of work actually demonstrated, and then sets out why the whole collection falls short of a mechanism.
One distinction governs everything that follows. Showing that a molecule attaches to a receptor is a binding result. Showing what that attachment does to the receptor's behaviour is a functional result. Showing that the functional change produces an effect in a living animal is a third thing again. Most ibogaine receptor data stops at the first or second step, and almost all of it comes from cell preparations or rodent tissue rather than people.
The headline finding
The reference survey is a 2019 review in Frontiers in Pharmacology, which gathered the in vitro binding literature. Its summary is that ibogaine binds numerous central nervous system targets at micromolar concentrations [1]. The micromolar detail matters: it means the concentrations required are relatively high, which is characteristic of a compound interacting weakly with many things rather than strongly with one.
That same review is the source of the most important sentence in this area. Having catalogued the binding, the authors state that these ibogaine-receptor interactions do not appear to account for the long-lasting effects of ibogaine observed in rodents [1]. They also state that the mechanism behind its ability to attenuate drug-seeking behaviour remains unresolved [1]. Both statements come from the paper that documents the receptor profile, not from critics of it.
What ibogaine binds
The documented targets, at micromolar range, include nicotinic acetylcholine receptors of the alpha3beta4 and alpha2beta4 subtypes, NMDA receptors, kappa and mu opioid receptors, the 5HT2A and 5HT3 serotonin receptors, and the dopamine and serotonin transporters [1]. A separate review of ibogaine's cardiac pharmacology gives a similar list, adding sigma receptors and glutamate receptors, and describes ibogaine in plain terms as a dirty drug [6].
That phrase is standard pharmacological usage rather than a criticism. A clean drug hits one target selectively; a dirty one interacts with many. Dirty drugs are harder to study because any observed effect may arise from any of the interactions, or from several in combination, and isolating the responsible one requires selectively blocking each in turn.
It is also worth noting what is absent from the list. There is no evidence of ibogaine acting at a single high-affinity site that would mark it as a selective agent for any one system. The breadth of the profile is the finding.
A practical consequence of that breadth is that the receptor list is a poor guide to what ibogaine will do in any individual. A selective drug produces a predictable effect because one pathway is engaged. A compound engaging a dozen pathways at overlapping concentrations produces effects whose balance depends on local receptor densities, on how much drug reaches each region, and on how quickly the person clears it. That is part of why ibogaine's effects differ so much between people, and why a receptor profile does not translate into a prediction.
Nicotinic acetylcholine receptors
The best-characterised interaction is at the alpha3beta4 nicotinic receptor. Work on human alpha3beta4 receptors expressed in cells found that ibogaine blocked receptor-driven calcium influx about nine times more potently than phencyclidine, and bound a single site within the ion channel itself with a dissociation constant of 0.46 micromolar [2].
That is a channel-blocking action rather than a receptor-activating one: ibogaine sits inside the pore and obstructs it. The authors also found binding slightly tighter when the receptor was in its desensitised state, and suggested this might hold the receptor desensitised for longer [2]. This is the one place where ibogaine's affinity approaches a concentration low enough to be plausibly relevant at treatment exposures.
The alpha3beta4 subtype attracted attention because structure-activity work on ibogaine analogs found that potency at this receptor correlated with effects on morphine self-administration in rats. The analog 18-MC is most potent as an alpha3beta4 antagonist, and reproduces much of ibogaine's effect on drug self-administration in rodents without ibogaine's tremor or cardiac action [7]. That correlation is the strongest circumstantial case that this receptor matters, and it remains a correlation in rodents.
Opioid receptors: blocker, not activator
The claim that ibogaine acts as an opioid agonist, and therefore substitutes for an opioid during withdrawal, is common and not supported by the better evidence. An earlier study had reported full agonism at the mu receptor. A subsequent investigation across three laboratories, including a replication of that earlier method, found the opposite [3].
In rat thalamic membranes, ibogaine, noribogaine and 18-MC all behaved as mu-opioid antagonists, with functional potencies of around 3 micromolar for ibogaine and 13 micromolar for noribogaine and 18-MC. Ibogaine stimulated G protein binding in none of the receptor-expressing cell lines tested. Noribogaine did not stimulate it in brain slices and was at most a weak partial agonist in a single cell line, and three separate laboratories found no stimulation by noribogaine in thalamic membranes [3].
The practical implication is direct. If ibogaine blocks the mu receptor rather than activating it, it is not providing opioid cover, and whatever relieves withdrawal is happening by some other route. That reframes the withdrawal question rather than answering it.
If something here speaks to your situation, the next step is a five-minute provider match profile. We read it personally, take your case to vetted providers, and come back with the ones who say yes — or tell you honestly if ibogaine is not the answer.
Find a providerThe kappa receptor and noribogaine
The kappa opioid receptor is where noribogaine, ibogaine's long-lived metabolite, shows its most distinctive profile. Cell-based assays found noribogaine to be 75 percent as efficacious as dynorphin A at activating G protein signalling, with a half-maximal concentration of 9 micromolar, but only 12 percent as efficacious at recruiting beta-arrestin, and it inhibited dynorphin-induced beta-arrestin recruitment at 1 micromolar [4].
A receptor can signal through more than one downstream pathway, and a compound favouring one over another is described as biased. Noribogaine is biased toward G protein signalling at the kappa receptor. The authors suggested this might explain why noribogaine lacks the dysphoric effects usually associated with kappa activation, since those effects are commonly attributed to the beta-arrestin pathway [4]. The profile differed from both ibogaine and 18-MC, which is a reason to treat parent drug and metabolite as pharmacologically distinct agents.
This is in vitro work with no human confirmation, and the concentrations involved are in the micromolar range. It is a plausible contributor to withdrawal relief, and it is labelled as such in the source rather than established.
Serotonin receptors and transporters
Ibogaine binds the 5HT2A and 5HT3 receptors and the serotonin transporter [1]. The 5HT2A receptor is the one through which classic psychedelics produce their effects, which is part of why ibogaine is grouped with them, though its binding there is weak compared with those drugs.
The functional work in animals is more informative. In rats given intravenous ibogaine or noribogaine, both compounds raised extracellular serotonin in the nucleus accumbens and both inhibited serotonin uptake at the transporter, with noribogaine approximately ten times more potent than ibogaine as an indirect serotonin agonist. Both also raised the stress hormones corticosterone and prolactin, and ibogaine produced dose-related tremor while noribogaine did not [5].
The same study reported a result that deserves more attention than it gets: neither compound changed dopamine in the nucleus accumbens [5]. Since the nucleus accumbens dopamine system is the one most often invoked in popular accounts of how ibogaine affects addiction, a direct measurement showing no change there is a meaningful negative finding.
NMDA receptors and the dirty drug problem
Ibogaine's binding at the NMDA glutamate receptor is documented [1] and has been proposed as a contributor to its effects, partly by analogy with other NMDA-blocking drugs that affect tolerance and dependence in animal models. The affinity is in the micromolar range, like most of the profile.
Here the dirty drug problem becomes acute. With this many targets engaged at broadly similar concentrations, attributing an effect to any one of them requires either a selective blocker of that target or a compound that hits it alone. The analog work with 18-MC is the closest the field has come, and it points toward the nicotinic receptor rather than NMDA [7].
One more structural point about the evidence base deserves stating. Nearly all of this work is in vitro, using receptors expressed in cell lines or membranes prepared from rodent brain. Those systems measure a molecule's interaction with an isolated receptor well, and they say nothing about what happens in an intact brain where the same receptor sits among others, in circuits with feedback, in a person whose liver is converting the drug into a different compound as the experiment proceeds. Extrapolating from a cell line to a clinical effect crosses several steps that are not trivial.
Why binding does not explain the effects
The central objection is a timing problem. Ibogaine's half-life in humans is short, and the receptor interactions documented are reversible: when the drug leaves, the receptor returns to normal. Yet the effects reported in animals, and claimed in humans, persist for weeks or months after the compound has cleared. Reversible binding cannot by itself produce a durable change, and this is the reasoning behind the review's statement that the receptor interactions do not appear to account for the long-lasting effects [1].
Alternative explanations therefore look past receptors to processes that outlast the drug, principally changes in growth factor signalling and in synaptic structure. Those hypotheses carry their own evidential problems and are examined separately. The point for this entry is that the receptor profile is the beginning of the mechanistic question and not the answer to it.
There is a further caution about concentration. Micromolar affinities are high relative to the plasma concentrations ibogaine reaches in treatment, which raises the question of whether some of the documented bindings occur meaningfully in a living person at all. A binding measured in a dish at a concentration never achieved in a human brain is a chemical fact without clinical consequence, and the literature does not consistently distinguish which of these interactions clear that bar.
None of this makes the receptor work useless. It rules things out, which is valuable: the mu-opioid findings undercut a specific and widely repeated claim about substitution, and the dopamine measurement undercuts another. It also identified the nicotinic receptor as the most promising lead, which in turn produced analogs that separate the anti-addictive effects from the cardiac ones in animals. Ruling out and narrowing down is how a mechanism eventually gets established, and the receptor literature has done both. What it has not done is support the confident mechanistic stories built on top of it.
Frequently asked questions
Which receptor matters most?
On current evidence the alpha3beta4 nicotinic receptor has the best case: ibogaine binds a single site in its ion channel at 0.46 micromolar [2], and analog potency at this receptor correlated with effects on morphine self-administration in rats [7]. It is not established.
Does ibogaine activate opioid receptors?
The better evidence says it blocks them. Across three laboratories ibogaine and noribogaine acted as mu-opioid antagonists, and ibogaine stimulated G protein binding in no cell line tested [3].
Does ibogaine affect dopamine?
It binds the dopamine transporter [1], but direct measurement in rats found no change in nucleus accumbens dopamine after either ibogaine or noribogaine [5].
Why is the mechanism still called unresolved?
Because the binding profile cannot explain durability. The review that catalogues the binding states that these interactions do not seem to account for the long-lasting effects seen in rodents, and that the mechanism remains unresolved [1].
References
- Marton S, Gonzalez B, Rodriguez-Bottero S, et al. 2019, Front Pharmacol 10:193. frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00193/full
- Arias HR, Rosenberg A, Targowska-Duda KM, et al. 2010, Int J Biochem Cell Biol 42(9):1525-1535. doi:10.1016/j.biocel.2010.05.011. PMID 20684041. doi.org/10.1016/j.biocel.2010.05.011
- Antonio T, Childers SR, Rothman RB, et al. 2013, PLoS One 8(10):e77262. doi:10.1371/journal.pone.0077262. PMC3818563. journals.plos.org/plosone/article?id=10.1371/journal.pone.0077262
- Maillet EL, Milon N, Heghinian MD, Fishback J, Schurer SC, Garamszegi N, Mash DC. 2015, Neuropharmacology 99:675-688. doi:10.1016/j.neuropharm.2015.08.032. PMID 26302653. doi.org/10.1016/j.neuropharm.2015.08.032
- Baumann MH, Rothman RB, Pablo JP, Mash DC. 2001, J Pharmacol Exp Ther 297(2):531-539. PMID 11303040. europepmc.org/article/MED/11303040
- Koenig X, Hilber K. 2015, Molecules 20(2):2208-2228. doi:10.3390/molecules20022208. PMC4382526. mdpi.com/1420-3049/20/2/2208
- Glick SD, Maisonneuve IM, Szumlinski KK. 2000, Ann N Y Acad Sci 914:369-386. doi:10.1111/j.1749-6632.2000.tb05211.x. PMID 11085336. europepmc.org/article/MED/11085336